ArticleFrontiers in pharmacology2026
Protein kinase C-λ drives third-degree burn-induced muscle wasting via STAT3-dependent catabolic pathways.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Severe burn injury triggers profound skeletal muscle atrophy through incompletely understood molecular mechanisms. This study investigated the role of protein kinase C (PKC) isoforms in burn-induced muscle wasting and evaluated potential therapeutic targets. Methods: We examined PKC isoform expression in skeletal muscle biopsies from burn patients with second-degree (n = 5) and third-degree burns (n = 5) at 7 days post-injury. Mouse burn models were established to investigate PKC signaling at 14 days post-injury. Muscle-specific PKC-lambda (PKC-λ) knockout mice and pharmacological inhibition with [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl] methyl dihydrogen phosphate (ICA-1) were employed. C2C12 myotubes were used for mechanistic studies with signal transducer and activator of transcription 3 (STAT3) overexpression experiments. Results: Among six PKC isoforms examined, only PKC-λ was selectively upregulated in third-degree versus second-degree burns in both humans and mice. Third-degree burns caused 39.5% muscle mass loss and 57.3% grip strength reduction, accompanied by PKC-λ activation and downstream STAT3-CCAAT/enhancer-binding protein delta (C/EBPδ)/myostatin catabolic signaling. Muscle-specific PKC-λ knockout mice showed significant protection against burn-induced muscle atrophy. Conclusion: PKC-λ serves as a critical upstream mediator linking severe burn injury to skeletal muscle atrophy through STAT3-C/EBPδ catabolic signaling. These findings establish PKC-λ as a promising therapeutic target for preventing burn-induced muscle wasting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.